Jasper Therapeutics (NASDAQ:JSPR) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw assumed coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report released on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $17.00 target price on the stock.

A number of other analysts have also recently weighed in on the company. Evercore ISI reduced their price target on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research report on Monday, September 22nd. BTIG Research cut their price objective on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. Finally, JMP Securities dropped their price target on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a research report on Monday, September 22nd. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $19.88.

Jasper Therapeutics Stock Up 5.4%

NASDAQ JSPR opened at $1.56 on Tuesday. The stock has a market capitalization of $43.65 million, a PE ratio of -0.26 and a beta of 3.07. Jasper Therapeutics has a 12-month low of $1.39 and a 12-month high of $7.19. The company has a 50 day moving average price of $1.77 and a two-hundred day moving average price of $2.52.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). As a group, equities analysts anticipate that Jasper Therapeutics will post -4.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in JSPR. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the first quarter worth approximately $46,000. Marex Group plc acquired a new position in Jasper Therapeutics during the 2nd quarter valued at $74,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the 2nd quarter valued at $78,000. Voleon Capital Management LP bought a new stake in Jasper Therapeutics in the 3rd quarter valued at $50,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Jasper Therapeutics by 11.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after purchasing an additional 23,453 shares during the period. 79.85% of the stock is owned by institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.